Naicker, V., Laher, F., Bekker, L.G., Seaton, K.E., Allen, M., De Rosa, S., Yates, N.L., Mkhize, N.N., Saunders, K., Heptinstall, J. and Malahleha, M., 2024. Safety and immunogenicity after a 30-month boost of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120/MF59 vaccine boost (HVTN 100): A phase 1–2 randomized double-blind placebo-controlled trial. PLOS Global Public Health, 4(9), p.e0003319.
Safety and immunogenicity after a 30-month boost of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120/MF59 vaccine boost (HVTN 100): A phase 1-2 randomized double-blind placebo-controlled trial.
- Journal Articles
